EP2389165A2 - Composition pharmaceutique de sel d'ibandronate de sodium ou d'hydrate correspondant - Google Patents

Composition pharmaceutique de sel d'ibandronate de sodium ou d'hydrate correspondant

Info

Publication number
EP2389165A2
EP2389165A2 EP10701131A EP10701131A EP2389165A2 EP 2389165 A2 EP2389165 A2 EP 2389165A2 EP 10701131 A EP10701131 A EP 10701131A EP 10701131 A EP10701131 A EP 10701131A EP 2389165 A2 EP2389165 A2 EP 2389165A2
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
weight
composition according
sodium salt
microcrystalline cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10701131A
Other languages
German (de)
English (en)
Inventor
Francisco JURADO SÁNCHEZ
José Miguel Rizo Martínez
Sergio Arroyo Hidalgo
Óscar Manjón Cembellín
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Liconsa SA
Original Assignee
Laboratorios Liconsa SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Liconsa SA filed Critical Laboratorios Liconsa SA
Priority to EP10701131A priority Critical patent/EP2389165A2/fr
Publication of EP2389165A2 publication Critical patent/EP2389165A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Definitions

  • the present invention relates to a direct compressed pharmaceutical composition of lbandronate sodium salt, to tablets containing it, and to their preparations processes.
  • lbandronate sodium is the International Nonproprietary Name (INN) of [3-(/V- methyl- ⁇ /'-pentyl)-amino-1 -hydroxypropane-1 ,1 -diphosphonic acid monosodium salt
  • lbandronate sodium is a third-generation nitrogen-containing bisphosphonate derivative characterized by an aliphatic tertiary amine side chain.
  • Bonviva® It was first disclosed in US patent 4,927,814. It is marketed under the name of Bonviva® for the treatment of bone disorders such as hypercalcaemia of malignancy, osteolysis, Paget's disease, osteoporosis, and metastatic bone disease. Bonviva® has a rapid dissolution profile where more than 60% of free lbandronic acid is dissolved up to 5 minutes and more than 85% up to 15 minutes (cf. figures 1 and 2). A suitable application of the active ingredient is its administration on one, two or three consecutive days per month.
  • international patent application WO 03/95029 discloses an intermittent regimen comprising the administration of at least 120% of the expected efficacious daily dose of bisphosphonate and one or more pharmaceutically acceptable excipients, for the prevention or treatment of disorders characterise by pathologically increased bone resorption.
  • Granulation compositions of bisphosphonates are known in the art.
  • US 2004137056 A1 is directed to a process for the preparation of pharmaceutical compositions of bisphosphonic acids by wet granulation. It discloses pharmaceutical compositions comprising about 30 to 50% by weight of microcrystalline cellulose and about 0.5 to 2% by weight of a disintegrant such as croscarmellose sodium.
  • the microcrystalline cellulose according to the specification can be Avicel PH 101 with a particle size of 50 ⁇ m and the content of croscarmellose is about 1 % by weight.
  • US 2008139514 A1 is directed to pharmaceutical composition of ibandronate sodium salt prepared by wet granulation. It discloses tablet formulations comprising ibandronate sodium salt, microcrystalline cellulose and crospovidone as disintegrant amongst other pharmaceutical excipients.
  • the microcrystalline cellulose according to the specification can be Avicel PH 101 with a particle size of 50 ⁇ m and the content of crospovidone is about 6% by weight.
  • WO 2008/74144 is directed to pharmaceutical composition of ibandronate amongst other bisphosphonic acids with vitamin D compound and other pharmaceutical excipients. It discloses tablet formulations comprising alendronate sodium trihydrate, microcrystalline cellulose and croscarmellose sodium.
  • the microcrystalline cellulose according to the specification can be Avicel PH 302 with a particle size of 100 ⁇ m and the content of croscarmellose ejemplified is about 4% by weight.
  • the use of granulation techniques for preparing pharmaceutical compositions of lbandronate sodium may produce the degradation of active ingredient.
  • the degradation of bisphosphonic acid is particularly pronounced in the presence of water and/or elevated temperature. It is supposed that this incompatibility is due to the reaction of the free amino group of the bisphosphonic acid with the glycosilic alcohol of a sugar, for example the binder. This reaction results in the formation of brown pigmented degradates and as a consequence the decrease of the effective dose of the active ingredient in the pharmaceutical composition.
  • Direct compression formulations have also been formulated in order to avoid the degradation of the active ingredient during granulation processes and tabletting.
  • international patent application WO 94/12200 and counterpart US 5681590 disclose that preparing a pharmaceutical composition of lbandronate sodium in the presence of lactose by direct compression, a pharmaceutical formulation where the bisphosponic acid is stable can be obtained.
  • biphosphonate sodium tablets comprising 0.5-40% by weight of a biphosphonic acid as active ingredient, 10-80% by weight of anhydrous lactose or hydrous fast flow lactose, 5-50% by weight of microcrystalline cellulose, 0.5-10% by weight of croscarmellose sodium and 0.1 -5% by weight of magnesium stearate.
  • lbandronic acid is selected amongst other biphosphonic acids for preparing these pharmaceutical compositions but there are not any specific example comprising it.
  • examples are directed to alendronic acid containing about 1 % of croscarmellose sodium and about 40% of microcrystalline cellulose where the particle size of the microcrystalline cellulose is not disclosed.
  • lbandronic acid and its salts must be administered over a long periods of time, therefore, oral pharmaceutical compositions are more accepted for patients.
  • oral treatment is complicated because of the low oral tolerability of bisphosphonic acid and particularly, aminobisphosphonic acid and its salts, which causes diseases of the upper gastrointestinal tract, such as gastrointestinal reflux disorders, esophagitis, dyspepsia and ulcers. It is also known that motility disorders may occur when swallowing the tablets to raise odynophagia or oesophageal strictures. Frequently, this is the case of elderly patients or those patients that are forced to take bisphosphonic acids in a lying position.
  • European patent application EP 936.913 discloses another orally coated form of lbandronate with an adjuvant coating or film-coating to reduce the gastrointestinal side effects of bisphosphonate.
  • the film-coating is dissolved in a short period of time independently of the pH value.
  • the active ingredient is dissolved in the stomach achieving a high local concentration. It is disclosed that the rapid dissolution profile of the active ingredient is due to the properties of the film-coating regardless of the composition of the core.
  • compositions of lbandronate sodium salt in tablets form comprising ibandronate sodium salt or other biphosphonate, microscrystalline cellulose of 50 ⁇ m and a maximum about 2% of croscarmellose sodium for compositions prepared by wet granulation and microcrystalline cellulose and a maximum about 1 % of croscarmellose sodium for compositions prepared by direct compression.
  • a pharmaceutical composition of lbandronate sodium salt or a hydrate thereof which comprises microcrystalline cellulose with a median particle size (D50) from 30 to 150 ⁇ m and croscarmellose sodium in an amount from 10 to 15% by weight of the total weight of the pharmaceutical composition, has an appropriate dissolution profile and also shows a good stability, being also advantageous because of it can be manufactured by a simple process. Moreover, the rapid dissolution of the active ingredient from the pharmaceutical composition decreases the gastrointestinal side effects when lbandronate sodium salt is orally administered.
  • D50 median particle size
  • an aspect of the present invention refers to a direct compressed pharmaceutical composition which comprises from 0.5 to 40% by weight of
  • Ibandronate sodium salt from 15 to 30% by weight of microcrystalline cellulose with a median particle size (D50) from 30 to 150 ⁇ m and from 10 to 15% by weight of croscarmellose sodium.
  • Another aspect of the present invention relates to a process for the preparation of the pharmaceutical composition as defined above, which comprises: (a) mixing lbandronate sodium salt with microcrystalline cellulose, a diluent, and croscarmellose sodium; (b) incorporating a lubricant to the mixture of step (a); (c) incorporating an anti-adherent to the mixture of step (b); and (d) direct compression of the mixture of step (c) to obtain a tablet.
  • FIG. 1 shows a comparative scheme of the dissolution profile between the marketed product (Bonviva®) and the pharmaceutical compositions of the present invention.
  • the dissolution tests fulfil the requirements of the Food and Drug Administration (FDA). Units of the scheme are as follows: w is water, d is the percentage of active ingredient dissolved in water and t is time in minutes.
  • the description of the percentages of croscarmellose and median particle size of microcrystalline cellulose of the pharmaceutical compositions is as follows: A comprises Avicel PH 102 and 15% croscarmellose; B is Bonviva® 150mg Lot. B1064; C comprises Avicel PH 102 and 5% croscarmellose; D comprises Avicel PH 102 and 10% croscarmellose and E comprises comprecel 200 (microcrystalline cellulose) and 10% croscarmellose.
  • FIG.2 shows a comparative scheme of the dissolution profile between the marketed product (Bonviva®) and the pharmaceutical compositions of the present invention.
  • the dissolution tests fulfil the requirements of the Food and Drug Administration (FDA). Units of the scheme are as follows: w is water, d is the percentage of active ingredient dissolved in water and t is time in minutes. The description of the percentages of croscarmellose and median particle size of microcrystalline cellulose of the pharmaceutical compositions A, B, C, D and E are the same as described in FIG. 1 and composition F comprises comprecel 200 and 15% croscarmellose.
  • median particle size refers to a median diameter or medium value of particle diameter. Thus, the 50% of particles are larger than the reference value and the other 50% are smaller.
  • lubricant refers to a material which prevents adhesion of the tablet material to the surface of the dies and punches, reduces interparticle friction, facilitates the ejection of the tablets from the die cavity, and may improve the rate of flow of the tablet granulation.
  • Commonly used lubricant includes talc, magnesium stearate, calcium stearate, stearic acid, glyceryl behanate, hydrogenated vegetable oils, and polyethylene glycol (PEG).
  • anti-adherent agent refers to a material which reduces the adhesion between the powder and the punch faces and thus prevents sticking to the tablet punches.
  • tablette refers to a compressed pharmaceutical dosage formulation of all shapes and sizes, whether coated or uncoated.
  • substances which may be used for coating tablets include, for instance, hydroxypropylmethylcellulose, hydroxypropylcellulose, titanium oxide, talc, sweeteners, and colorants.
  • superdisintegrant agent refers to a type of disintegrant that swells from four to forty fold in less than 30 seconds when placed in an aqueous medium.
  • Superdisintegrants commonly used are Veegum HV, methylcellulose, agar, bentonite, cellulose and wood products, natural sponge, pectin, cation exchange resins, alginic acid, guar gum, citrus pulp, starch, and carboxymethylcellulose.
  • Preferred superdisintegrants are croscarmellose sodium, crospovidone, sodium starch glycolate or mixtures thereof.
  • percentage (%) by weight refers to the percentage of each ingredient of the pharmaceutical composition in relation to the total weight of the tablet.
  • an aspect of the present invention refers to a direct compressed pharmaceutical composition of lbandronate sodium salt or a hydrate thereof which comprises microcrystalline cellulose with a median particle size (D50) from 30 to 150 ⁇ m and from 10 to 15% by weight of croscarmellose sodium.
  • D50 median particle size
  • croscarmellose sodium can be considered a superdisintegrant. It is known that a superdisintegrant agent is commonly used in the manufacturing of tablets. This name comes from the low levels (2-4%) at which they are completely effective. In particular, croscarmellose sodium is used in tablet formulations, as well in direct compression as wet granulation processes.
  • concentrations of up to 5% w/w of croscarmellose sodium are used as a tablet disintegrant, although normally 2% w/w is used in tablets prepared by direct compression and 3% w/w in tablets prepared by a wet granulation process (cf. Handbook of Pharmaceutical Excipients. Kibbe, Arthur H, Pharmaceutical Press. 3 rd edition, pp.160).
  • the required dissolution profile of the lbandronate sodium salt or a hydrate thereof can be achieved by a tablet comprising microcrystalline cellulose having a specific median particle size (D50), in particular from 30 to 150 ⁇ m, together with croscarmellose sodium in an amount from 10 to 15%.
  • D50 median particle size
  • croscarmellose sodium in an amount from 10 to 15%.
  • the target dissolution profile comprises that more than 60% of free lbandronic acid is dissolved up to 5 minutes and more than 85% up to 15 minutes (cf. figures 1 and 2). Moreover, the high concentration of active ingredient in the stomach also reduces the gastrointestinal side effects.
  • the lbandronate sodium salt is a monohydrate. In another particular embodiment, the lbandronate sodium salt is a hemihydrate.
  • the median particle size (D50) of microcrystalline cellulose is from 50 to 120 ⁇ m. In another particular embodiment, the median particle size (D50) of microcrystalline cellulose is from 80 to 110 ⁇ m. In a preferred embodiment, the median particle size (D50) of microcrystalline cellulose is 100 ⁇ m. It means that the 50% of particles of microcrystalline cellulose are smaller than 100 ⁇ m.
  • the pharmaceutical composition comprises from 11 to 15% by weight of croscarmellose sodium. In a more preferred embodiment, the composition comprises from 12 to 15% by weight of croscarmellose sodium. In a particular embodiment the composition comprises from 13 to 15% by weight of croscarmellose sodium. In another particular embodiment the composition comprises from 14 to 15% by weight of croscarmellose sodium. In another more preferred embodiment the composition comprises 15% by weight of croscarmellose sodium.
  • the pharmaceutical composition comprises 36% by weight of lbandronate sodium salt or a hydrate thereof.
  • the percentage of 36% by weight of lbandronate sodium salt can represent between 50-150 mg of free lbandronic acid in relation to the total weight of the tablet.
  • This quantity of the free active ingredient is suitable for its administration daily to 50 mg or once per month to 150 mg.
  • the intermittent regimen that is once monthly, may improve the level of compliance of the treatment, as well as management and patient satisfaction.
  • the pharmaceutical composition is administered once per month.
  • the pharmaceutical composition is administered once daily.
  • the pharmaceutical composition further comprises a diluent selected from the group consisting of anhydrous lactose, hydrous fast flow lactose, calcium carbonate, dibasic calcium phosphate, dextrose, fructose, isomaltose, magnesium carbonate, magnesium oxide, mannitol, maltose, sorbitol, sodium alginate, sucrose and xylitol.
  • a diluent selected from the group consisting of anhydrous lactose, hydrous fast flow lactose, calcium carbonate, dibasic calcium phosphate, dextrose, fructose, isomaltose, magnesium carbonate, magnesium oxide, mannitol, maltose, sorbitol, sodium alginate, sucrose and xylitol.
  • the diluent is selected from anhydrous lactose and hydrous fast flow lactose. Both diluents are widely used in direct compression of tablets.
  • the pharmaceutical composition
  • the pharmaceutical composition comprises: 36.7% by weight of lbandronate sodium salt or a hydrate thereof; 25.3% by weight of microcrystalline cellulose; 14.7% by weight of croscarmellose sodium; 19.3% by weight fast flow lactose; 1 % by weight of magnesium stearate; and 1 % by weight of colloidal anhydrous silica.
  • the pharmaceutical composition of the invention is especially appropriate for the preparation of tablets by direct compression.
  • the tablets can be film- coating tablets.
  • the film-coating comprises hydroxypropylcellulose, titanium dioxide, and polyethylenglycol 6000. This film- coating is independently of the pH value so; a high concentration of free lbandronic acid is achieved in a short period of time, obtaining the required dissolution profile.
  • the pharmaceutical composition comprises from 0.5 to 40% by weight of lbandronate sodium salt or a hydrate thereof, from 15 to 30% by weight of microcrystalline cellulose with a median particle size (D50) from 30 to 150 ⁇ m and from 10 to 15% by weight of croscarmellose sodium, and is manufactured by direct compression to obtain a tablet.
  • the dissolution profile of these tablets comprises that more than 60% of free lbandronic acid is dissolved up to 5 minutes and more than 85% up to 15 minutes.
  • Monohydrate lbandronate sodium salt is commercially available as Bonviva®. From the list of excipients of the technical data sheet of Bonviva®, it follows that the process for the manufacturing of the corresponding film-coating tablet may imply a granulation process. Due to the instability of the lbandronate sodium salt in the presence of wetting agents, such as water, and/or elevated temperature, excipients and conditions commonly used in wet granulation and dry granulation, it is desirable to be able to formulate the lbandronate sodium salt by direct compression, avoiding degradation of the active ingredient and the need of a precise control of the formulation conditions when dry or wet granulation techniques are used.
  • wetting agents such as water, and/or elevated temperature
  • excipients and conditions commonly used in wet granulation and dry granulation it is desirable to be able to formulate the lbandronate sodium salt by direct compression, avoiding degradation of the active ingredient and the need of a precise control of the formulation conditions when dry or wet granulation techniques are used
  • excipients of the present invention allows formulating the tablets by direct compression which is advantageous for the reasons mentioned above.
  • the direct compression process of the present invention requires only blending the ingredients in an appropriate order without granulation and avoids the use of binders, water and/or high temperatures, wherein the lbandronate sodium salt could degrade.
  • the stability of the active ingredient in the pharmaceutical formulation of the present invention was confirmed with a three-month data stability test (cf. example 2).
  • compositions of the invention can be prepared by a process which comprises: (a) mixing lbandronate sodium salt or a hydrate thereof with microcrystalline cellulose, a diluent, and croscarmellose sodium; (b) incorporating a lubricant to the mixture of step (a); (c) incorporating an anti- adherent to the mixture of step (b); and (d) direct compression of the mixture of step (c) to obtain a tablet.
  • the lbandronate sodium salt or a hydrate thereof is previously sieved through a sieve of 813 ⁇ m; the lubricant and the anti- adherent are sieved through a sieve of 600 ⁇ m.
  • Example 1 Process for manufacturing a film-coating tablet by direct compression
  • the tablet composition is as follow: Core Tablet
  • the percentage of each ingredient is referred to the total weight of the tablet.
  • the core weight is 450 mg and the total weight is 465mg, the amount of active ingredient per tablet is equivalent to 150 mg of free lbandronic acid. Process for manufacturing of the core tablet
  • Lactose fast-flow, microcrystalline cellulose, sieved monohydrate lbandronate sodium salt (equivalent to 150 mg free lbandronic acid per tablet) thought a sieve of 813 ⁇ m and sodium croscarmellose were consecutively added to a blender. The mixture was blended for 12 minutes at 13 rpm. Colloidal anhydrous silica previously sieved thought a sieve of 600 ⁇ m was added to the mixture and was blended for 3 minutes at 13 rpm. Finally, the magnesium stearate previously sieved thought a sieve of 600 ⁇ m was added to the mixture and blended for 3 minutes at 13 rpm. The lubricated mixture was compressed to provide tablets of 150 mg of free lbandronic acid as monohydrate lbandronate sodium salt.
  • Tablets were compressed on a Fette 102i rotary tablet press.
  • the rotor speed was 50.000 tablets per hour
  • the fill-o-matik speed was 25 rpm
  • Obtained tablets had a median hardness of 141.4N and 0.03% of friability.
  • the film-coating suspension was prepared by blending PEG 6000 in water until dissolution. Titanium dioxide was added to the obtained dissolution and blended until homogenization. Finally, hydroxypropylcellulose (HPC) was added to the mixture and blended also until homogenization.
  • HPC hydroxypropylcellulose
  • the film-coating were performed using a Manesty XL Lab 01 coater, with a tablet charge of 900 g and a feed air temperature of 50 0 C.
  • the sprayed flow rate is 9.4 g/min.
  • the final total weight of obtained tablets is 458.5 mg and the increase percentage of tablets weight is 2%.
  • Comparative Example 1 Dissolution profile.
  • the target dissolution profile requires that more than 60% of free lbandronic acid is dissolved up to 5 minutes and more than 85% up to 15 minutes.
  • composition A comprises Avicel PH 102 and 15% croscarmellose.
  • Comparative pharmaceutical composition B is Bonviva® (Reference of dissolution profile required) 150mg Lot. B1064 in water.
  • Comparative pharmaceutical composition C comprises Avicel PH 102 and 5% croscarmellose.
  • composition D comprises Avicel PH 102 and 10% croscarmellose.
  • Comparative pharmaceutical composition E comprises comprecel 200 and
  • Comparative pharmaceutical composition F comprises comprecel 200 and
  • the dissolution profile results show that the pharmaceutical composition of the invention (A and D) have the required dissolution profile as Bonviva. Thus, more than 60% of free lbandronic acid is dissolved up to 5 minutes and more than 85% up to 15 minutes.
  • Comparative pharmaceutical composition C (having 5% croscarmellose, outside the claimed range) gives rise to a different dissolution profile, which is considered not appropriate. Thus, at 5 minutes only a 45.7% of free lbandronic acid is dissolved and at 15 minutes only a 77.1% of free lbandronic acid is dissolved. Comparative pharmaceutical compositions E and F (using microcrystalli ⁇ e cellulose having a median particle size outside the claimed S range) give rise also to a different dissolution profile. Thus, at 5 minutes only a 47.6% and 19,0% of free lbandronic acid are respectively dissolved. Besides, at 15 minutes only a 60.7% of free lbandronic acid is dissolved in composition F.
  • the analytical method used to determine the percentage of monohydrate ibandronate sodium salt (assay) in the tablets of the present invention was high performance liquid chromatography (HPLC) with an index refraction detector.
  • the active ingredient is stable in the pharmaceutical compositions of the present invention, both when the pharmaceutical composition as a tablet is packaged in an Aluminium/Triplex blisters and when is packaged in an Aluminium/Aluminium blisters.
  • the active ingredient in the pharmaceutical compositions of the present invention is also stable when a less protective packaging material is used, such as Triplex.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique à base de sel sodique d'ibandronate ou d'un hydrate de celui-ci, comprenant de la cellulose microcristalline dont la taille moyenne des particules (D50) varie de 30 à 150 µm, ainsi que de la croscarmellose sodique à hauteur de 10 à 15 % en poids. L'invention concerne également un comprimé à base de ladite composition pharmaceutique et son procédé de fabrication par compression directe.
EP10701131A 2009-01-22 2010-01-19 Composition pharmaceutique de sel d'ibandronate de sodium ou d'hydrate correspondant Withdrawn EP2389165A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10701131A EP2389165A2 (fr) 2009-01-22 2010-01-19 Composition pharmaceutique de sel d'ibandronate de sodium ou d'hydrate correspondant

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382008A EP2210596A1 (fr) 2009-01-22 2009-01-22 Composition pharmaceutique de sel d'ibandronate de sodium ou d'hydrate correspondant
PCT/EP2010/050557 WO2010084111A2 (fr) 2009-01-22 2010-01-19 Composition pharmaceutique à base de sel sodique d'ibandronate ou d'un hydrate de celui-ci
EP10701131A EP2389165A2 (fr) 2009-01-22 2010-01-19 Composition pharmaceutique de sel d'ibandronate de sodium ou d'hydrate correspondant

Publications (1)

Publication Number Publication Date
EP2389165A2 true EP2389165A2 (fr) 2011-11-30

Family

ID=40674186

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09382008A Withdrawn EP2210596A1 (fr) 2009-01-22 2009-01-22 Composition pharmaceutique de sel d'ibandronate de sodium ou d'hydrate correspondant
EP10701131A Withdrawn EP2389165A2 (fr) 2009-01-22 2010-01-19 Composition pharmaceutique de sel d'ibandronate de sodium ou d'hydrate correspondant

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP09382008A Withdrawn EP2210596A1 (fr) 2009-01-22 2009-01-22 Composition pharmaceutique de sel d'ibandronate de sodium ou d'hydrate correspondant

Country Status (2)

Country Link
EP (2) EP2210596A1 (fr)
WO (1) WO2010084111A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013081562A1 (fr) * 2011-10-13 2013-06-06 Mahmut Bilgic Formulations orales comprenant de l'ébastine
WO2013062498A1 (fr) * 2011-10-13 2013-05-02 Mahmut Bilgic Formulations orales solides comprenant de l'ébastine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
RU2387451C2 (ru) 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
CA2671727C (fr) * 2006-12-20 2016-02-16 Genpharm Ulc Composition contenant un acide bisphosphonique combine a de la vitamine d

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010084111A2 *

Also Published As

Publication number Publication date
WO2010084111A2 (fr) 2010-07-29
WO2010084111A3 (fr) 2010-10-07
EP2210596A1 (fr) 2010-07-28

Similar Documents

Publication Publication Date Title
CN106943355B (zh) 药物组合物
CN100551377C (zh) 用于治疗和预防骨质疏松症的二膦酸
KR101442862B1 (ko) 만니톨 또는 유당을 함유하는 고형 제제
US20050026871A1 (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
US20100151019A1 (en) SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF
US6623755B2 (en) Pharmaceutical tablets
US20160106766A1 (en) Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d
US20140335176A1 (en) Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing
US8987285B2 (en) Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof
US20120039963A1 (en) 3-(2-Dimethlaminomethyl Cyclohexyl)Phenol Retard Formulation
US20260115169A1 (en) Pharmaceutical composition of darolutamide
EP1463488B1 (fr) Composition pharmaceutique comprenant de la poudre de lait ecreme
EP2389165A2 (fr) Composition pharmaceutique de sel d'ibandronate de sodium ou d'hydrate correspondant
CA2517372C (fr) Composition pharmaceutique a base d'acide alendronique, de sels ou d'esters de celui-ci et procede de preparation de cette composition
US20130165459A1 (en) Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
JP2024067030A (ja) ミラベグロン含有放出制御医薬組成物及びその製造方法
US11648242B2 (en) Pharmaceutical composition comprising pimavanserin, process of preparation and use thereof
WO2006018033A1 (fr) Formulations de bisphosphonates
JP5774308B2 (ja) 水溶性ビノレルビン塩の安定な医薬組成物
WO2015198225A1 (fr) Composition pharmaceutique orale à base de tofacinitib
EP1491199B1 (fr) cOMPOSITION pharmaceutique d'Alendronate de Sodium Trihydrate et procédé de préparation de celle-ci& x9;
JP6982290B2 (ja) オンジエキス含有内服用固形医薬製剤
SK11072000A3 (sk) Tiagabínové prostriedky s predĺženým uvoľňovaním so zníženými vedľajšími účinkami
US20150158891A1 (en) Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor
CA3238703A1 (fr) Comprime enrobe de film comprenant du tofacitinib micronise

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110822

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/20 20060101AFI20140917BHEP

Ipc: A61K 31/663 20060101ALI20140917BHEP

Ipc: A61K 9/36 20060101ALI20140917BHEP

Ipc: A61K 9/28 20060101ALN20140917BHEP

INTG Intention to grant announced

Effective date: 20141007

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150218